Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 253


An Experimenter's Guide to Glioblastoma Invasion Pathways.

de Gooijer MC, Guillén Navarro M, Bernards R, Wurdinger T, van Tellingen O.

Trends Mol Med. 2018 Sep;24(9):763-780. doi: 10.1016/j.molmed.2018.07.003. Epub 2018 Jul 30. Review.


Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer.

Wang C, Jin H, Gao D, Lieftink C, Evers B, Jin G, Xue Z, Wang L, Beijersbergen RL, Qin W, Bernards R.

J Hepatol. 2018 Jul 18. pii: S0168-8278(18)32184-6. doi: 10.1016/j.jhep.2018.07.004. [Epub ahead of print]


Taking advantage of drug resistance, a new approach in the war on cancer.

Wang L, Bernards R.

Front Med. 2018 Aug;12(4):490-495. doi: 10.1007/s11684-018-0647-7. Epub 2018 Jul 18.


A system-wide approach to monitor responses to synergistic BRAF and EGFR inhibition in colorectal cancer cells.

Ressa A, Bosdriesz E, de Ligt J, Mainardi S, Maddalo G, Prahallad A, Jager M, de la Fonteijne L, Fitzpatrick M, Groten S, Altelaar AFM, Bernards R, Cuppen E, Wessels L, Heck AJR.

Mol Cell Proteomics. 2018 Jul 3. pii: mcp.RA117.000486. doi: 10.1074/mcp.RA117.000486. [Epub ahead of print]


Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies.

Rizzolio S, Cagnoni G, Battistini C, Bonelli S, Isella C, Van Ginderachter JA, Bernards R, Di Nicolantonio F, Giordano S, Tamagnone L.

J Clin Invest. 2018 Aug 31;128(9):3976-3990. doi: 10.1172/JCI99257. Epub 2018 Aug 13.


SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.

Mainardi S, Mulero-Sánchez A, Prahallad A, Germano G, Bosma A, Krimpenfort P, Lieftink C, Steinberg JD, de Wit N, Gonçalves-Ribeiro S, Nadal E, Bardelli A, Villanueva A, Bernards R.

Nat Med. 2018 Jul;24(7):961-967. doi: 10.1038/s41591-018-0023-9. Epub 2018 May 28.


MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.

Xue Z, Vis DJ, Bruna A, Sustic T, van Wageningen S, Batra AS, Rueda OM, Bosdriesz E, Caldas C, Wessels LFA, Bernards R.

Cell Res. 2018 Jul;28(7):719-729. doi: 10.1038/s41422-018-0044-4. Epub 2018 May 24.


ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.

Berns K, Caumanns JJ, Hijmans EM, Gennissen AMC, Severson TM, Evers B, Wisman GBA, Jan Meersma G, Lieftink C, Beijersbergen RL, Itamochi H, van der Zee AGJ, de Jong S, Bernards R.

Oncogene. 2018 May 15. doi: 10.1038/s41388-018-0300-6. [Epub ahead of print]


An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.

Wang L, Leite de Oliveira R, Huijberts S, Bosdriesz E, Pencheva N, Brunen D, Bosma A, Song JY, Zevenhoven J, Los-de Vries GT, Horlings H, Nuijen B, Beijnen JH, Schellens JHM, Bernards R.

Cell. 2018 May 31;173(6):1413-1425.e14. doi: 10.1016/j.cell.2018.04.012. Epub 2018 May 10.


PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart M, von Minckwitz G, Baselga J.

Ann Oncol. 2018 Apr 26. doi: 10.1093/annonc/mdx803. [Epub ahead of print] No abstract available.


Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.

Caumanns JJ, Berns K, Wisman GBA, Fehrmann RSN, Tomar T, Klip H, Meersma GJ, Hijmans EM, Gennissen AMC, Duiker EW, Weening D, Itamochi H, Kluin RJC, Reyners AKL, Birrer MJ, Salvesen HB, Vergote I, van Nieuwenhuysen E, Brenton J, Braicu EI, Kupryjanczyk J, Spiewankiewicz B, Mittempergher L, Bernards R, van der Zee AGJ, de Jong S.

Clin Cancer Res. 2018 Aug 15;24(16):3928-3940. doi: 10.1158/1078-0432.CCR-17-3060. Epub 2018 Apr 23.


Anti-cancer therapy: senescence is the new black.

Leite de Oliveira R, Bernards R.

EMBO J. 2018 May 15;37(10). pii: e99386. doi: 10.15252/embj.201899386. Epub 2018 Apr 18. No abstract available.


A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma.

Wang C, Jin H, Gao D, Wang L, Evers B, Xue Z, Jin G, Lieftink C, Beijersbergen RL, Qin W, Bernards R.

Cell Res. 2018 Jun;28(6):690-692. doi: 10.1038/s41422-018-0020-z. Epub 2018 Mar 5. No abstract available.


A Computational Workflow Translates a 58-Gene Signature to a Formalin-Fixed, Paraffin-Embedded Sample-Based Companion Diagnostic for Personalized Treatment of the BRAF-Mutation-Like Subtype of Colorectal Cancers.

In 't Veld SGJG, Duong KN, Snel M, Witteveen A, Beumer IJ, Delahaye LJMJ, Wehkamp D, Bernards R, Glas AM, Tian S.

High Throughput. 2017 Nov 6;6(4). pii: E16. doi: 10.3390/ht6040016.


PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.

Brunen D, de Vries RC, Lieftink C, Beijersbergen RL, Bernards R.

Mol Cancer Ther. 2018 Apr;17(4):849-857. doi: 10.1158/1535-7163.MCT-17-0868. Epub 2018 Feb 13.


High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer.

Wang L, Leite de Oliveira R, Wang C, Fernandes Neto JM, Mainardi S, Evers B, Lieftink C, Morris B, Jochems F, Willemsen L, Beijersbergen RL, Bernards R.

Cell Rep. 2017 Oct 17;21(3):773-783. doi: 10.1016/j.celrep.2017.09.085.


Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival.

Clarke CN, Lee MS, Wei W, Manyam G, Jiang ZQ, Lu Y, Morris J, Broom B, Menter D, Vilar-Sanchez E, Raghav K, Eng C, Chang GJ, Simon I, Bernards R, Overman M, Mills GB, Maru D, Kopetz S.

Ann Surg Oncol. 2017 Dec;24(13):4051-4058. doi: 10.1245/s10434-017-6054-5. Epub 2017 Sep 21.


The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.

Severson TM, Wolf DM, Yau C, Peeters J, Wehkam D, Schouten PC, Chin SF, Majewski IJ, Michaut M, Bosma A, Pereira B, Bismeijer T, Wessels L, Caldas C, Bernards R, Simon IM, Glas AM, Linn S, van 't Veer L.

Breast Cancer Res. 2017 Aug 25;19(1):99. doi: 10.1186/s13058-017-0861-2.


In vivo veritas: Finding novel genes involved in liver cancer through in vivo genetic screens.

Wang C, Bernards R.

Hepatology. 2017 Dec;66(6):2078-2080. doi: 10.1002/hep.29382. Epub 2017 Oct 30. No abstract available.


Identification of a Druggable Pathway Controlling Glioblastoma Invasiveness.

Pencheva N, de Gooijer MC, Vis DJ, Wessels LFA, Würdinger T, van Tellingen O, Bernards R.

Cell Rep. 2017 Jul 5;20(1):48-60. doi: 10.1016/j.celrep.2017.06.036.


Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data.

Sinha S, Thomas D, Chan S, Gao Y, Brunen D, Torabi D, Reinisch A, Hernandez D, Chan A, Rankin EB, Bernards R, Majeti R, Dill DL.

Nat Commun. 2017 May 31;8:15580. doi: 10.1038/ncomms15580.


A breast cancer gene signature for indolent disease.

Delahaye LJMJ, Drukker CA, Dreezen C, Witteveen A, Chan B, Snel M, Beumer IJ, Bernards R, Audeh MW, Van't Veer LJ, Glas AM.

Breast Cancer Res Treat. 2017 Jul;164(2):461-466. doi: 10.1007/s10549-017-4262-0. Epub 2017 Apr 27.


Clinical Trials Series — Large Pharma.

Schellens JHM, Bernards RN.

N Engl J Med. 2017 Apr 6;376(14):e28. doi: 10.1056/NEJMc1701621. No abstract available.


Drug therapy: Exploiting synthetic lethality to improve cancer therapy.

Brunen D, Bernards R.

Nat Rev Clin Oncol. 2017 Jun;14(6):331-332. doi: 10.1038/nrclinonc.2017.46. Epub 2017 Mar 29. No abstract available.


How Much Longer Will We Put Up With $100,000 Cancer Drugs?

Workman P, Draetta GF, Schellens JHM, Bernards R.

Cell. 2017 Feb 9;168(4):579-583. doi: 10.1016/j.cell.2017.01.034.


A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.

Wang L, Šuštić T, Leite de Oliveira R, Lieftink C, Halonen P, van de Ven M, Beijersbergen RL, van den Heuvel MM, Bernards R, van der Heijden MS.

Eur Urol. 2017 Jun;71(6):858-862. doi: 10.1016/j.eururo.2017.01.021. Epub 2017 Jan 17.


Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer.

Beumer IJ, Persoon M, Witteveen A, Dreezen C, Chin SF, Sammut SJ, Snel M, Caldas C, Linn S, van 't Veer LJ, Bernards R, Glas AM.

Biomark Insights. 2016 Dec 11;11:139-146. eCollection 2016.


Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening.

Verissimo CS, Overmeer RM, Ponsioen B, Drost J, Mertens S, Verlaan-Klink I, Gerwen BV, van der Ven M, Wetering MV, Egan DA, Bernards R, Clevers H, Bos JL, Snippert HJ.

Elife. 2016 Nov 15;5. pii: e18489. doi: 10.7554/eLife.18489.


Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.

Berns K, Sonnenblick A, Gennissen A, Brohée S, Hijmans EM, Evers B, Fumagalli D, Desmedt C, Loibl S, Denkert C, Neven P, Guo W, Zhang F, Knijnenburg TA, Bosse T, van der Heijden MS, Hindriksen S, Nijkamp W, Wessels LF, Joensuu H, Mills GB, Beijersbergen RL, Sotiriou C, Bernards R.

Clin Cancer Res. 2016 Nov 1;22(21):5238-5248. Epub 2016 May 12.


FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer.

Theelen WS, Mittempergher L, Willems SM, Bosma AJ, Peters DD, van der Noort V, Japenga EJ, Peeters T, Koole K, Šuštić T, Blaauwgeers JL, van Noesel CJ, Bernards R, van den Heuvel MM.

J Pathol Clin Res. 2016 Aug 13;2(4):223-233. eCollection 2016 Oct.


Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling.

Brunen D, García-Barchino MJ, Malani D, Jagalur Basheer N, Lieftink C, Beijersbergen RL, Murumägi A, Porkka K, Wolf M, Zwaan CM, Fornerod M, Kallioniemi O, Martínez-Climent JÁ, Bernards R.

Oncotarget. 2016 Jun 21;7(25):37407-37419. doi: 10.18632/oncotarget.9822.


70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators.

N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253.


Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.

Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filiciotto G, Marzolla G, Elez E, van Geel RM, Bartolini A, Crisafulli G, Boscaro V, Godfrey JT, Buscarino M, Cancelliere C, Linnebacher M, Corti G, Truini M, Siravegna G, Grasselli J, Gallicchio M, Bernards R, Schellens JH, Tabernero J, Engelman JA, Sartore-Bianchi A, Bardelli A, Siena S, Corcoran RB, Di Nicolantonio F.

Cancer Res. 2016 Aug 1;76(15):4504-15. doi: 10.1158/0008-5472.CAN-16-0396. Epub 2016 Jun 16.


PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart M, von Minckwitz G, Baselga J.

Ann Oncol. 2016 Aug;27(8):1519-25. doi: 10.1093/annonc/mdw197. Epub 2016 May 13.


CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes.

Evers B, Jastrzebski K, Heijmans JP, Grernrum W, Beijersbergen RL, Bernards R.

Nat Biotechnol. 2016 Jun;34(6):631-3. doi: 10.1038/nbt.3536. Epub 2016 Apr 25.


A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.

Vecchione L, Gambino V, Raaijmakers J, Schlicker A, Fumagalli A, Russo M, Villanueva A, Beerling E, Bartolini A, Mollevi DG, El-Murr N, Chiron M, Calvet L, Nicolazzi C, Combeau C, Henry C, Simon IM, Tian S, in 't Veld S, D'ario G, Mainardi S, Beijersbergen RL, Lieftink C, Linn S, Rumpf-Kienzl C, Delorenzi M, Wessels L, Salazar R, Di Nicolantonio F, Bardelli A, van Rheenen J, Medema RH, Tejpar S, Bernards R.

Cell. 2016 Apr 7;165(2):317-30. doi: 10.1016/j.cell.2016.02.059.


Equivalence of MammaPrint array types in clinical trials and diagnostics.

Beumer I, Witteveen A, Delahaye L, Wehkamp D, Snel M, Dreezen C, Zheng J, Floore A, Brink G, Chan B, Linn S, Bernards R, van 't Veer L, Glas A.

Breast Cancer Res Treat. 2016 Apr;156(2):279-87. doi: 10.1007/s10549-016-3764-5. Epub 2016 Mar 22.


FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.

Koole K, Brunen D, van Kempen PM, Noorlag R, de Bree R, Lieftink C, van Es RJ, Bernards R, Willems SM.

Clin Cancer Res. 2016 Aug 1;22(15):3884-93. doi: 10.1158/1078-0432.CCR-15-1874. Epub 2016 Mar 2.


Targeting the RB-E2F pathway in breast cancer.

Johnson J, Thijssen B, McDermott U, Garnett M, Wessels LF, Bernards R.

Oncogene. 2016 Sep 15;35(37):4829-35. doi: 10.1038/onc.2016.32. Epub 2016 Feb 29. Review.


DNA-Guided Precision Medicine for Cancer: A Case of Irrational Exuberance?

Voest EE, Bernards R.

Cancer Discov. 2016 Feb;6(2):130-2. doi: 10.1158/2159-8290.CD-15-1321.


Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma.

Heynen GJ, Nevedomskaya E, Palit S, Jagalur Basheer N, Lieftink C, Schlicker A, Zwart W, Bernards R, Bajpe PK.

Mol Cancer Res. 2016 May;14(5):411-22. doi: 10.1158/1541-7786.MCR-15-0291-T. Epub 2016 Jan 19.


Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

Michaut M, Chin SF, Majewski I, Severson TM, Bismeijer T, de Koning L, Peeters JK, Schouten PC, Rueda OM, Bosma AJ, Tarrant F, Fan Y, He B, Xue Z, Mittempergher L, Kluin RJ, Heijmans J, Snel M, Pereira B, Schlicker A, Provenzano E, Ali HR, Gaber A, O'Hurley G, Lehn S, Muris JJ, Wesseling J, Kay E, Sammut SJ, Bardwell HA, Barbet AS, Bard F, Lecerf C, O'Connor DP, Vis DJ, Benes CH, McDermott U, Garnett MJ, Simon IM, Jirström K, Dubois T, Linn SC, Gallagher WM, Wessels LF, Caldas C, Bernards R.

Sci Rep. 2016 Jan 5;6:18517. doi: 10.1038/srep18517.


Treatment Individualization in Colorectal Cancer.

van Geel RM, Beijnen JH, Bernards R, Schellens JH.

Curr Colorectal Cancer Rep. 2015;11(6):335-344. Epub 2015 Aug 26. Review.


An integrated genomic approach identifies that the PI3K/AKT/FOXO pathway is involved in breast cancer tumor initiation.

Smit L, Berns K, Spence K, Ryder WD, Zeps N, Madiredjo M, Beijersbergen R, Bernards R, Clarke RB.

Oncotarget. 2016 Jan 19;7(3):2596-610. doi: 10.18632/oncotarget.6354.


Radical Sabbaticals.

Clevers H, Firestein S, Ringrose L, Bernards R, Darwin KH, Vance RE.

Cell. 2015 Nov 5;163(4):788-9. doi: 10.1016/j.cell.2015.10.058. No abstract available.


The consensus molecular subtypes of colorectal cancer.

Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S.

Nat Med. 2015 Nov;21(11):1350-6. doi: 10.1038/nm.3967. Epub 2015 Oct 12.


Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response.

Lips EH, Michaut M, Hoogstraat M, Mulder L, Besselink NJ, Koudijs MJ, Cuppen E, Voest EE, Bernards R, Nederlof PM, Wesseling J, Rodenhuis S, Wessels LF; Center for Personalized Cancer Treatment.

Breast Cancer Res. 2015 Oct 3;17(1):134. doi: 10.1186/s13058-015-0642-8.


PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.

Prahallad A, Heynen GJ, Germano G, Willems SM, Evers B, Vecchione L, Gambino V, Lieftink C, Beijersbergen RL, Di Nicolantonio F, Bardelli A, Bernards R.

Cell Rep. 2015 Sep 29;12(12):1978-85. doi: 10.1016/j.celrep.2015.08.037. Epub 2015 Sep 10.


NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor.

Galvani E, Sun J, Leon LG, Sciarrillo R, Narayan RS, Sjin RT, Lee K, Ohashi K, Heideman DA, Alfieri RR, Heynen GJ, Bernards R, Smit EF, Pao W, Peters GJ, Giovannetti E.

Oncotarget. 2015 Dec 15;6(40):42717-32. doi: 10.18632/oncotarget.3956.


BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.

Severson TM, Peeters J, Majewski I, Michaut M, Bosma A, Schouten PC, Chin SF, Pereira B, Goldgraben MA, Bismeijer T, Kluin RJ, Muris JJ, Jirström K, Kerkhoven RM, Wessels L, Caldas C, Bernards R, Simon IM, Linn S.

Mol Oncol. 2015 Oct;9(8):1528-38. doi: 10.1016/j.molonc.2015.04.011. Epub 2015 May 7.

Supplemental Content

Loading ...
Support Center